Key result
Pentazocine significantly improved survival times compared to control (60 vs. 16 hours; P < 0.01) and enhanced left ventricular function in a rat model of postresuscitation myocardial dysfunction.
Why the study?
Does pentazocine reduce the severity of postresuscitation myocardial dysfunction and improve survival in a rat model of ventricular fibrillation?
Does pentazocine reduce the severity of postresuscitation myocardial dysfunction and improve survival in a rat model of ventricular fibrillation?
Absolute Event Rate: 60% vs 16%
p-value: p=< 0.01
In a rat model of cardiac arrest, the delta-opioid receptor agonist pentazocine reduced postresuscitation myocardial dysfunction and improved survival, suggesting a potential role for pharmacological hibernation during CPR.
No takes yet. Share an insight, caveat, or question.
May reduce postresuscitation dysfunction in rats; leaves open translation of delta-opioid agonism to human resuscitation trials.
Sun et al. (2004) studied Postresuscitation myocardial dysfunction (n=15). Pentazocine vs. Saline placebo or pentazocine pretreated with naloxone was evaluated on Survival time (p=< 0.01). Pentazocine significantly improved survival times compared to control (60 vs. 16 hours; P < 0.01) and enhanced left ventricular function in a rat model of postresuscitation myocardial dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: